spacer
home > ebr > winter 2018 > back to the future
PUBLICATIONS
European Biopharmaceutical Review

Back to the Future

Globally, levels of antimicrobial resistance (AMR) are rising, and the shortage of effective medicines to treat microbial diseases such as pneumonia is severe. New approaches and innovations are urgently needed, but, for this to be realised, the way antibiotics are defined needs to change. Classes of medicines, such as vaccines and other immunotherapies, need to be brought into the fold. The challenge is that such new therapies will only progress to the clinic if stronger global efforts and financial support programmes encourage small enterprises to enter the market.

Using pneumococcal pneumonia as an example, this article explores the promising approaches that could prevent and cure this disease in vulnerable and developing populations and looks at the broader context of developing immunotherapeutic approaches to tackle growing levels of antimicrobial resistance.

Moving Beyond the Traditional


Given the increased threat of AMR, expanding the scope and classes of antimicrobial treatments beyond traditional smallmolecule drugs is important. Traditional antibiotics are facing increased resistance, and a spectrum of other treatments could play a significant role in combatting the rise of multi-drugresistant strains. Non-traditional classes of antibiotics include a wide range of combination therapies, phage therapy and immunotherapies such as antisera, antibodies and, particularly, vaccines given their preventive nature.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonas Elliott Gerson is co-founder and Director of Operations at PnuVax SL Biopharmaceuticals, Canada. He oversees product licensing, manufacturing and delivery of vaccines, including those for pneumonia and yellow fever. Jonas’s previous roles have included biopharmaceutical engineering and fuel cell research. He has an MASc in chemical engineering from Queen’s University, Canada.

Dr Donald Gerson is President and Chief Executive Officer of PnuVax SL Biopharmaceuticals, Canada, and has many years’ experience in vaccine and biopharma manufacturing management. He is former President and Chief Operating Officer of Celltrion and was previously Managing Director for manufacturing at Wyeth-Lederle Vaccines and Pediatrics. Donald has produced many vaccines to prevent and treat bacterial infections, as well as experimental vaccines for HIV and other diseases. Donald has also designed and constructed many biotech facilities around the world. He has a PhD in biophysics from McGill University, Canada.
spacer
Jonas Elliott Gerson
spacer
spacer
spacer
Dr Donald Gerson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control

Berlinger & Co AG

There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement